Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
We are seeking to out-license our product portfolio to territories where we do not have sales and marketing operations More
Decapinol™ rinse contains a cationic surfactant Delmopinol Hydrochloride 2mg/ml; Decapinol rinse has a unique mode of action, which prevents the attachment as well as the adherence of plaque bacteria to the teeth, gingiva and to itself. More
We are seeking to out-license our innovative Soluleaves range More
Cellophil™ is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
SALINUM™ is a saliva substitute, indicated for the relief of symptoms of dry mouth, or xerostomia. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
This ORS effervescent tablet has been developed according to the latest guidelines of the WHO. We are looking for partners in Europe and in other areas to commercialize the ORS effervescent tablets More
Looking for partners to distribute highly innovative and effective oral care, skin care and Gynaecological pharmaceuticals More
Decapinol Gel, offers a novel and convenient way of treating periodontal disease. It contains 3 key ingredients - Delmopinol Hydrochloride (5mg/ml), Polyvinylpyrrolidone (PVP) and Hyaluronic Acid. More
New formulation of Xanthan gum prepared using a combination of extrusion and heat followed by milling. The formulation disperses in water in just a few seconds and gives a higher viscosity than non-processed xanthan. More
Your selection
- Therapeutic target
- Oral Health del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Aphthous ulcers
- Dental disorder (other)
- Gingivitis
- Gum disease
- Herpes simplex virus type 1 (oral)
- Mouth disorder (other)
- Mucositis oral
- Mucositis, Radiation-induced
- Periodontal disease
- Tooth decay
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us